Lucy Liu

Tell us about your expertise in the laboratory sector with a brief about your organisation, its initiatives, and the journey to date.

Shenzhen New Industries Biomedical Engineering Co., Ltd. (briefed as Snibe) is located in the National Biological Industry Park (Shenzhen, China), was founded in 1995, and has focused on the IVD field for 29 years. Snibe's products have now covered more than 152 countries globally, with installations of over 29,500 units. Moreover, Snibe provides one of the broadest chemiluminescence immunoassay test menus with 236 parameters, covering more than 22 test panels including thyroid, fertility, infectious disease, tumor markers, and so on.  

In your opinion, what areas in the laboratory sector are expected to evolve and what role is your organisation expected to play?

At Snibe, we're devoted to delivering top clinical diagnostic solutions and focus on the traceability of products. With certifications from multiple authoritative organizations and active participation in esteemed quality assessment programs to meet the international standard, our commitment to excellence remains unwavering. Additionally, Snibe is expected to expand into more possibilities in the laboratory sector. This year, we will bring our new member from our biochemistry and molecular diagnostics product line and welcome witness to our breakthrough on Booth Z5.C30.

Give us an insight into your portfolio and solutions targeted at the Middle East region.

The Middle East is a potential research platform for developing the healthcare industry. With the increasing demand for healthcare technology and solutions in the Middle East region, its role in global healthcare is also becoming increasingly important. Snibe will continue to strive to provide high-quality in vitro diagnostic solutions and promote innovative development of in vitro diagnostic testing technology. The Middle East will be a vibrant and rapidly growing market.

Tell us about your recent and upcoming investments and partnerships.

Snibe will continue to pay attention to the needs of the international market, committed to providing high-quality and comprehensive in vitro diagnostic services for global laboratories and promoting the development of the healthcare industry through efficient and accurate product performance. At the same time, Snibe will continue to be committed to the demand of the international market and hopes to enhance clinical laboratory technology exchanges in the international region and expand international scientific and technological exchanges and cooperation through Medlab Middle East 2024.

What can visitors expect to see at your booth in Medlab Middle East 2024? What opportunities are you looking forward to?

In the past 29 years, Snibe has focused on the field of in-vitro diagnostics and created an independent research and development product ecology integrating "reagents, instruments, and raw materials.". Snibe will firmly fulfill its corporate mission, "customer-centric, market-oriented, and continuously promote the healthcare industry through continuous product and technological innovation. To be a pioneer in the global diagnosis field is our vision. Snibe's striving for excellence never ends.

Please tell us about your plans for the year 2024.

Snibe is excited to introduce our latest products and innovations to the world. We are grateful to the Medlab Organizing Committee for providing us with this global platform and we look forward to achieving great results together at Medlab Middle East 2024.

Is there anything else you would like to add?

At Medlab Middle East 2024, Snibe will bring its highly anticipated CLIA products, the MAGLUMI X-Series and one of the broadest CLIA test menu up to 236 parameters. In addition, Snibe will also bring new products from the clinical biochemistry and Molecular Diagnosis product lines, continuously providing customers with comprehensive clinical laboratory diagnostic solutions. We hope to communicate with more international partners and seize more market information and opportunities at Medlab Middle East 2024.